Nov. 10, 2022—Vanderbilt research describes a new investigational peptide drug that can penetrate immune and nonimmune cells, and block inflammatory signaling in a preclinical model of atopic dermatitis — eczema.
Nov. 8, 2022—Vanderbilt researchers found that a protein with roles in innate immunity worsens memory at baseline in carriers of APOE-e4, the strongest genetic risk factor for Alzheimer’s disease, further implicating neuroinflammation in cognitive decline.
Study sheds light on the development of inflammation, high blood pressure and resulting kidney damage
Oct. 20, 2022—by Bill Snyder Researchers at Vanderbilt University Medical Center have found that the change in a single letter of the genetic code promotes, in a mouse model, the development of inflammation, high blood pressure and resulting kidney damage. Their findings, featured Oct. 14 on the cover of Circulation Research, suggest that targeting inflammatory cytokines, signaling...
Aug. 25, 2022—Gastrointestinal inflammation, such as occurs in inflammatory bowel disease, triggers the expansion of a population of “bone-eating” cells, leading to bone loss.
Aug. 17, 2022—A Vanderbilt research team has discovered that activation of a certain protein complex involved in the inflammatory response in immune cells contributes to salt-sensitive hypertension.